Breast Cancer Research and Treatment

, Volume 163, Issue 2, pp 343–348 | Cite as

Breast cancer screening in patients with cancers other than breast

  • Robin B. Leopold
  • Alexander W. Thomas
  • Kyle F. Concannon
  • Alissa D. Correll
  • Catherine M. LaPenta
  • Stephen M. Maurer
  • Brian L. Sprague
  • Sally D. Herschorn
  • Claire F. Verschraegen



Screening mammography can detect early breast cancers and reduce subsequent cancer mortality. However, there is a lack of consensus as to when to discontinue screening. The absence of clear-cut guidelines on when not to screen means that many patients with advanced malignancies continue screening despite unclear benefit.


We performed a retrospective cohort study of female patients diagnosed with a non-breast malignancy to explore the incidence and effects of screening mammography. Female patients diagnosed with a non-breast malignancy stage II or higher between 2007 and 2012 were identified through the Vermont Cancer Registry and cross-referenced with mammography screening logs from January 1, 2007 to September 30, 2014. Additional data were collected through chart review, in May 2016.


Twenty-six percent of women (398/1501) with a stage II or greater cancer (other than breast) diagnosed between 2007 and 2012 had a screening mammogram within the first 5 years of their diagnosis. Of these 398 women, 193 (48.5%) were alive without cancer, 132 (33.2%) had died, and 73 (18.3%) were alive with cancer at the time of chart review. Of those who died, 84 (63.6%) had a stage III or IV cancer. Eighteen (4.5%) had a breast biopsy following a screening mammogram suspicious for cancer, resulting in 13 (3.3%) benign diagnoses and 5 (1.3%) breast cancer diagnoses. No patient died of breast cancer.


Except for highly curable cancers, female patients diagnosed with an advanced non-breast malignancy experienced mortality that outweighs a breast cancer mortality benefit from screening mammography as estimated from prior studies.


Breast Cancer Thyroid Cancer Lymphedema Breast Cancer Screening Screen Mammography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We would like to thank Lisa Thompson, Cancer Registry, Vermont Dept. of Health Information Management and Mark Bowman, Vermont Breast Cancer Surveillance System for their support. The collection of screening mammography records by the Vermont Breast Cancer Surveillance System was supported by Grant Nos. U54 CA163303 and P01 CA154292 from the National Cancer Institute.


There was no funding for this study.

Compliance with ethical standards

Conflict of interest

Dr. Sally Herschorn owns stock in Hologic, Inc. All other authors declare that they have no conflict of interest.

Ethical approval

The study received a waiver of consent form. All procedures performed in this study involved registry data from human participants and were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Siu AL (2016) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164:279–296CrossRefPubMedGoogle Scholar
  2. 2.
    Smith RA, Andrews K, Brooks D et al (2016) Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 66:95–114CrossRefGoogle Scholar
  3. 3.
    Moyer VA (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120–134CrossRefPubMedGoogle Scholar
  4. 4.
    US Preventive Services Task Force (1996) Guide to clinical preventive services: report of the U.S. Preventive Services Task Force, 2nd edn. Williams & Wilkins, Baltimore. 18, Screening for Thyroid Cancer. Available from:
  5. 5.
    Myers ER, Moorman P, Gierisch JM et al (2015) Benefits and harms of breast cancer screening: a systematic review. JAMA 314:1615–1634CrossRefPubMedGoogle Scholar
  6. 6.
    Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613CrossRefPubMedGoogle Scholar
  7. 7.
    Ong MS, Mandl KD (2015) National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Affairs (Project Hope) 34:576–583CrossRefGoogle Scholar
  8. 8.
    Lansdorp-Vogelaar I, Gulati R, Mariotto AB et al (2014) Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 161:104–112CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sima CS, Panageas KS, Schrag D (2010) Cancer screening among patients with advanced cancer. JAMA 304:1584–1591CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    SEER Cancer Statistics Review (1975–2013) National Cancer Institute. July 2016, at
  11. 11.
    Epner DE, Baile WF (2014) Difficult conversations: teaching medical oncology trainees communication skills one hour at a time. Acad Med J Assoc Am Med Coll 89:578–584CrossRefGoogle Scholar
  12. 12.
    Monsees B, Destouet JM, Evens RG (1988) The self-referred mammography patient: a new responsibility for radiologists. Radiology 166:69–70CrossRefPubMedGoogle Scholar
  13. 13.
    Joseph K, Vrouwe S, Kamruzzaman A et al (2012) Outcome analysis of breast cancer patients who declined evidence-based treatment. World J Surg Oncol 10:118CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bloom HJ, Richardson WW, Harries EJ (1962) Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J 2:213–221CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Verkooijen HM, Fioretta GM, Rapiti E et al (2005) Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg 242:276–280CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Robin B. Leopold
    • 1
  • Alexander W. Thomas
    • 1
  • Kyle F. Concannon
    • 1
  • Alissa D. Correll
    • 1
  • Catherine M. LaPenta
    • 1
  • Stephen M. Maurer
    • 1
  • Brian L. Sprague
    • 1
  • Sally D. Herschorn
    • 1
  • Claire F. Verschraegen
    • 1
  1. 1.University of Vermont Cancer CenterBurlingtonUSA

Personalised recommendations